Qatar

The primary regulatory authority governing health products in Qatar is the Ministry of Public Health (MOPH), operating through its Health Technology Assessment and Pharmaceutical Affairs departments. The overarching legal framework is established under Law No. 8 of 1969 on the Practice of Medicine, Dentistry and Nursing, and subsequent amendments, alongside the Pharmacy and Drug Control Law. More recent regulatory architecture has been reinforced through Ministerial Decisions that align Qatar's approval processes with international standards. All medical devices, diagnostics, digital health solutions, and pharmaceuticals must be registered with the MOPH before they can be marketed, imported, or distributed within Qatar. The registration process involves a formal dossier submission, technical evaluation, and, for certain product categories, local conformity assessments and post-market surveillance commitments.

Key submission requirements mandate that applicants designate a locally registered importer or authorized representative based in Qatar, who bears regulatory responsibility for the product throughout its lifecycle. Pharmaceutical dossiers are generally accepted in the Common Technical Document (CTD) format, in alignment with ICH guidelines, while reference to approvals from stringent regulatory authorities (such as the US FDA, EMA, or UK MHRA) can facilitate expedited review pathways. Medical devices typically require evidence of conformity with recognized international standards such as ISO 13485 and CE marking or equivalent approval from an SRA. Qatar has undertaken notable regulatory modernization efforts in the lead-up to and following major international events, including enhanced digital submission portals, strengthened pharmacovigilance requirements, and increased harmonization efforts with Gulf Cooperation Council (GCC) member states through the GCC Standardization Organization (GSO) and the Gulf Health Council frameworks.

Public procurement of health products in Qatar is centrally coordinated through the Ministry of Public Health and its affiliated institutions, with Hamad Medical Corporation (HMC) serving as the principal public healthcare provider and the dominant institutional buyer. HMC manages its own procurement and supply chain operations for hospitals, specialty centers, and community health facilities across the country. Large-scale or high-value tenders are subject to the Public Procurement Law (Law No. 24 of 2015) and are overseen by the Central Tenders Committee, which mandates competitive tendering processes, transparency in award decisions, and compliance with Qatari financial regulations. The Primary Health Care Corporation (PHCC) manages procurement for primary care and community health facilities independently, creating two distinct institutional procurement channels within the public sector. Suppliers must typically be registered with the relevant institution's vendor database and may be required to demonstrate local representation, after-sales service capacity, and adherence to product registration requirements as conditions of tender eligibility.

The private healthcare sector in Qatar is growing steadily, driven by a diversifying economy, an expatriate-heavy population, and government encouragement of private investment in healthcare. Private hospitals, polyclinics, and diagnostic centers procure health products through direct commercial channels, relying on local distributors and authorized agents. Qatar does not have a significant donor-funded procurement landscape comparable to lower-income markets, and mechanisms such as UNICEF Supply Division, the Global Fund, Gavi, or USAID procurement channels are not primary routes to market given Qatar's high-income country status. However, Qatar does engage in international health diplomacy and humanitarian health initiatives, and products supplied through such frameworks must still comply with MOPH registration requirements. Qatar's National Vision 2030 and its healthcare strategy promote local manufacturing and in-country value creation, with incentives available through Qatar Free Zones Authority (QFZA) and other economic development bodies, encouraging manufacturers to consider local production or packaging partnerships as a means of strengthening market access and tender competitiveness.